Zhitong Financial App News, Beida Pharmaceutical (300558.SZ) issued an announcement. Today, the company received an announcement from the National Drug Administration (“NMPA”) regarding ensartinib hydrochloride capsules (trade name: Bemena®, “Ensatinib”) for “patients with anaplastic lymphoma kinase (ALK) positive stage IB to stage IIB non-small cell lung cancer patients. Patients must have undergone surgical resection treatment in the past, and the doctor decides whether to accept or not receive adjuvant chemotherapy” (“surgery” for short) “Post-adjuvant treatment indications”) “Drug Registration Certificate”, this is Ensatinib is the third approved indication.

After obtaining the “Drug Registration Certificate”, the company can use this product for approved post-operative adjuvant treatment indications. This approval has a positive effect on the company's revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.